Dosing and uses of Alamast (pemirolast ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.1% (1mg/mL)
Allergic Conjunctivitis
Instill 1-2 gtt in affected eye(s) four times daily
Treatment duration ranges between a few days up to 4 weeks
Pediatric dosage forms and strengths
ophthalmic solution
- 0.1% (1 mg/mL)
Allergic Conjunctivitis
<3 years: Safety and efficacy not established
>3 years: As adults; instill 1-2 gtt in affected eye(s) four times daily
Treatment duration ranges between a few days up to 4 weeks
Alamast (pemirolast ophthalmic) adverse (side) effects
1-10%
Burning
Dry eyes
Foreign body sensation
Ocular discomfort
Allergy
Bronchitis
Cough
Sneezing
Nasal congestion
Warnings
Contraindications
Hypersensitivity
Cautions
For ophthalmic use only
Pregnancy and lactation
Pregnancy category: C
Lactation: Distributed in breast milk; caution advised
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Alamast (pemirolast ophthalmic)
Mechanism of action
Mast cell stabilizer; inhibits type-I immediate hypersensitivity reaction; also may inhibit mast cell release of inflammatory mediators and chemotaxis of eosinophils
Pharmacokinetics
Half-Life: 4.5 hr (systemic measurement after 2 weeks of ophthalmic administration)
Peak Plasma Time: 0.4 hr
Peak Plasma Concentration: 4.7 ng/mL (after 2 weeks of ophthalmic administration
Excretion: Urine (10-15% unchanged)
